After conducting an extensive colorectal cancer screening study involving 10,000 patients ages 50 to 84, Madison-based Exact Sciences announced the results. The test demonstrated 92% sensitivity for the detection of colorectal cancer and 42% sensitivity for polyps equal to or greater than 2 centimeters.
Company officials were pleased with the results, but investors evidently wanted more. On the day of the announcement, Exact Sciences’ stock shares fell by as much as 30%.
